Same-day Strattera appointment in Texas

If you’ve been diagnosed with ADHD—or suspect you might have it—you’ve probably wondered: Can I get medication through telehealth? The short answer is yes, especially for non-stimulant medications like Strattera (atomoxetine). But navigating the regulatory landscape can feel overwhelming, with federal rules, state laws, and provider restrictions all playing a role.

This guide breaks down everything you need to know about getting ADHD non-stimulant medication via telehealth in 2025, including current laws, state-by-state differences, and practical tips for accessing safe, effective care from the comfort of your home.

Understanding Non-Stimulant ADHD Medications

Before diving into telehealth regulations, it’s helpful to understand what non-stimulant ADHD medications are—and why they’re treated differently under the law.

What Are Non-Stimulant ADHD Medications?

Unlike stimulant medications (such as Adderall or Ritalin), non-stimulant ADHD medications work through different brain mechanisms and are not classified as controlled substances by the Drug Enforcement Administration (DEA). The most commonly prescribed non-stimulant is Strattera (atomoxetine), though others include guanfacine (Intuniv) and clonidine (Kapvay).

Key characteristics of Strattera:

• Not a controlled substance, meaning no DEA scheduling
• No potential for abuse or dependency
• Can be prescribed with refills (unlike stimulants that require new prescriptions monthly)
• Often prescribed in 90-day supplies for convenience
• Takes 4-6 weeks to reach full effectiveness (unlike stimulants that work within hours)
• FDA-approved for children age 6 and older, as well as adults

Why Does the Legal Status Matter?

Because Strattera and other non-stimulants aren’t controlled substances, they fall outside the strict federal prescribing regulations that govern stimulant medications. This means:

• No mandatory in-person exam required by federal law
• No DEA-imposed restrictions on telehealth prescribing
• Greater flexibility in how providers can evaluate and treat patients remotely
• Simpler refill processes

This regulatory difference makes non-stimulant ADHD medications particularly well-suited for telehealth treatment.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules: What You Need to Know in 2025

The federal landscape for telehealth prescribing has evolved significantly since the COVID-19 pandemic. Here’s where things stand as of late 2025.

The Ryan Haight Act and Its Exceptions

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 normally requires an in-person medical evaluation before a practitioner can prescribe controlled substances (Schedule II-V) via the internet. This law was designed to prevent online ‘pill mills’ from operating without proper oversight.

However, this requirement only applies to controlled substances. Since Strattera and other non-stimulant ADHD medications aren’t controlled, they were never subject to the Ryan Haight Act’s in-person requirement—even before the pandemic.

COVID-19 Telehealth Flexibilities

When the public health emergency began in 2020, the DEA temporarily waived the in-person requirement for controlled substances, allowing providers to prescribe stimulant ADHD medications via telehealth. This flexibility has been extended multiple times.

Current status as of December 2025:

• The ‘Third Temporary Extension’ allows telehealth prescribing of Schedule II-V controlled substances (including stimulants like Adderall) through December 31, 2025
• A fourth extension for 2026 is under review but not yet finalized
• Non-stimulant medications like Strattera remain unrestricted by federal telehealth rules

What Happens After December 31, 2025?

The DEA is expected to either:

1. Extend the telehealth flexibilities again
2. Implement new permanent rules (possibly a ‘Special Registration’ system for telehealth providers)
3. Allow the temporary rules to expire, which would reinstate the in-person requirement for controlled substances

Important: Even if federal rules change for stimulants, non-stimulant ADHD medications will continue to be prescribable via telehealth without special restrictions, since they were never subject to the Ryan Haight Act in the first place.

State-by-State Telehealth Laws: Key Differences

While federal law sets the baseline, individual states can—and do—impose additional requirements. Here’s what you need to know about major states and their telehealth ADHD medication policies.

States with No Special Restrictions

California, Illinois, Pennsylvania, Georgia

These states generally allow telehealth prescribing of non-controlled ADHD medications with no mandatory in-person visits. Providers must be licensed in the state and follow standard-of-care guidelines, but the telehealth format itself doesn’t create additional barriers.

California note: Pending legislation (AB 1503) may further clarify that a telehealth exam satisfies the requirement for a ‘prior exam’ before prescribing, though this hasn’t significantly impacted non-controlled medication access.

States with Annual Follow-Up Requirements

New Hampshire, Alabama

New Hampshire updated its laws in August 2025 to remove initial in-person requirements but now mandates at least an annual follow-up evaluation for patients receiving controlled medications via telehealth. For non-controlled medications like Strattera, this doesn’t apply—though regular follow-ups remain best practice.

Alabama requires patients receiving ongoing telehealth treatment to have an in-person visit within 12 months, though this rule includes a mental health exemption. Since ADHD is a psychiatric condition, many telehealth ADHD treatments fall under this exception. However, Alabama also has strict requirements about having a nurse or medical professional physically present during certain telehealth visits for controlled substance prescriptions.

States with Stricter Controlled Substance Rules

New York

New York reinstated an in-person evaluation requirement in May 2025 for prescribing any controlled substance via telehealth. This means:

• Patients seeking stimulant ADHD medications (like Adderall) must have an initial in-person exam
• Non-stimulant medications like Strattera are NOT affected and can be prescribed via telehealth without an in-person visit
• This represents one of the stricter state approaches nationally

Florida

Florida generally prohibits telehealth prescribing of Schedule II substances (which includes stimulants) unless the medication is for a psychiatric disorder, hospice care, or nursing facility treatment. Fortunately, ADHD qualifies as a psychiatric disorder, so stimulant prescriptions via telehealth are allowed under this exception.

For Strattera and other non-stimulants, Florida has no special restrictions—standard telehealth rules apply.

Special Notes on Texas

Texas is generally telehealth-friendly for mental health care, with no blanket prohibition on ADHD treatment via telemedicine. However, nurse practitioners and physician assistants in Texas cannot prescribe Schedule II stimulants in outpatient settings—they can only do so in hospitals or hospice care.

This restriction doesn’t affect:

• Physicians prescribing any ADHD medication via telehealth
• NPs/PAs prescribing non-stimulant medications like Strattera

Who Can Prescribe ADHD Medications via Telehealth?

Provider credentials matter—not every healthcare professional has the same prescribing authority, especially when it comes to controlled substances.

Physicians (MD/DO)

Licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth in all 50 states, provided they:

• Are licensed in the patient’s state
• Have a valid DEA registration (if prescribing controlled substances)
• Follow standard diagnostic and prescribing practices

Nurse Practitioners (NPs)

NP prescribing authority varies significantly by state:

Independent practice states (including NY, IL, NH, CA): NPs can prescribe all ADHD medications, including stimulants, after meeting experience requirements. In these states, NPs don’t need physician oversight for most prescribing decisions.

Collaborative practice states (including FL, TX, PA): NPs must work under a physician collaboration agreement. However:

• All can prescribe non-stimulant medications like Strattera with appropriate collaboration
• Stimulant prescribing varies—some states allow it with physician delegation, others restrict it

Highly restricted states (including GA): Georgia does not allow NPs to prescribe Schedule II controlled substances at all, even under physician supervision. However, NPs can still prescribe Strattera and other non-controlled ADHD medications.

Physician Assistants (PAs)

PAs generally practice under physician supervision nationwide. Their Schedule II prescribing authority mirrors many of the same state restrictions as NPs:

• Texas limits PA Schedule II prescribing to hospital/hospice settings
• Most states allow PAs to prescribe non-controlled medications with appropriate supervision

Bottom line: If you’re seeking non-stimulant ADHD medication via telehealth, you’ll have access to a broader range of qualified providers—physicians, NPs, and PAs—compared to stimulant medications, which face more restrictive rules in certain states.

The Telehealth ADHD Evaluation Process

Wondering what to expect during a telehealth ADHD evaluation? Legitimate providers follow comprehensive diagnostic protocols—not ‘quick quiz’ approaches.

Before Your Appointment

Most reputable telehealth platforms will ask you to:

• Complete detailed intake questionnaires about your symptoms, medical history, and mental health
• Provide information about symptom onset (ADHD symptoms must be present before age 12 for diagnosis)
• Fill out standardized ADHD rating scales
• Possibly gather input from family members or submit documentation like report cards (especially for young adults seeking diagnosis)

During the Video Consultation

A thorough telehealth ADHD evaluation typically includes:

Symptom assessment: Your provider will ask about attention difficulties, hyperactivity, impulsivity, and how these affect work, school, and relationships. They’re using DSM-5 diagnostic criteria, which require symptoms in multiple settings.

Medical history review: Expect questions about other health conditions, medications, substance use history, and family psychiatric history. This helps rule out other explanations for your symptoms and identify any safety concerns.

Mental status examination: Even via video, providers assess your presentation, speech, mood, thought process, and cognitive functioning.

Discussion of treatment options: A good provider will explain both medication and non-medication approaches (like therapy, coaching, lifestyle modifications). They’ll discuss the differences between stimulants and non-stimulants, including Strattera’s benefits and potential side effects.

Safety screening: Providers must screen for contraindications—conditions that would make certain medications unsafe. For Strattera specifically, they’ll check for narrow-angle glaucoma, recent MAOI use, severe cardiovascular disease, or liver problems.

Red Flags to Avoid

Steer clear of telehealth services that:

• Guarantee medications before evaluation
• Don’t require a video visit (phone-only consultations are insufficient for controlled substances in most states)
• Skip comprehensive symptom assessment
• Don’t check your identity or medical history
• Offer to ship medications from overseas

These are signs of potentially illegal or unsafe operations—not legitimate healthcare.

Prescription Monitoring and Safety Requirements

Even though Strattera isn’t a controlled substance, providers still follow important safety protocols.

Prescription Drug Monitoring Programs (PDMPs)

Most states require healthcare providers to check the state PDMP before prescribing controlled substances. While Strattera prescriptions don’t trigger these mandatory checks (since it’s not controlled), many providers still review PDMP data as part of comprehensive care to:

• Identify potential drug interactions
• Understand your full medication history
• Screen for concerning patterns (like multiple providers)

State-Specific PDMP Requirements

Follow-Up Care and Monitoring

Responsible telehealth ADHD treatment includes:

Initial follow-up (2-4 weeks): Your provider will check how you’re tolerating the medication and whether you’re experiencing side effects. With Strattera, it’s important to remember that full benefits may take 4-6 weeks, so patience is key.

Ongoing monitoring: Regular appointments (often monthly initially, then every 3-6 months) to assess:

• Symptom improvement
• Side effects (Strattera can affect blood pressure, heart rate, appetite, and mood)
• Medication adherence
• Need for dose adjustments

Coordination with other providers: Telehealth prescribers should communicate with your primary care doctor or therapist (with your permission) to ensure comprehensive care.

Common Questions About Telehealth ADHD Treatment

Can I get Strattera prescribed on my first telehealth visit?

Possibly, but it depends on the thoroughness of your evaluation and whether you have prior ADHD documentation. Some providers may prescribe after a comprehensive initial assessment, while others prefer to review records from previous providers or schedule additional evaluation time. No legitimate provider will prescribe without a proper diagnostic evaluation.

Will my pharmacy fill a telehealth prescription?

Yes, in nearly all cases. E-prescriptions sent from licensed telehealth providers are treated the same as in-person prescriptions. Some pharmacies briefly scrutinized stimulant prescriptions from certain telehealth companies in 2023 due to regulatory investigations, but this rarely affects non-controlled medications like Strattera.

Pro tip: Using a consistent pharmacy and a reputable telehealth service (like Klarity Health, which works with licensed providers and follows all regulatory requirements) helps ensure smooth prescription fills.

What if I need to switch from a stimulant to a non-stimulant?

Your telehealth provider can help manage this transition. Reasons patients switch to Strattera include:

• Side effects from stimulants (anxiety, sleep problems, appetite suppression)
• History of substance use concerns
• Preference for a medication without abuse potential
• Cardiovascular issues that contraindicate stimulants

The transition process typically involves tapering the stimulant while starting Strattera, with close monitoring during the switch.

Are telehealth ADHD evaluations covered by insurance?

Many insurance plans now cover telehealth mental health visits at the same rate as in-person care, thanks to pandemic-era policy changes that many states have made permanent. However, coverage varies by:

• Your specific insurance plan
• The telehealth provider’s network status
• Your state’s telehealth parity laws

Klarity Health accepts both insurance and cash pay, with transparent pricing so you know costs upfront. If you’re paying out-of-pocket, telehealth visits are often more affordable than traditional in-person psychiatry appointments.

What happens if I move to a different state?

This is important: providers must be licensed in the state where the patient is physically located during the appointment. If you move, you’ll typically need to find a new provider licensed in your new state. Some multi-state telehealth platforms can help transition your care, but you should inform your provider of any planned moves well in advance.

Can telehealth providers treat children and adolescents?

Yes, but with some limitations. Many telehealth ADHD services:

• Require parental/guardian involvement for minors
• Set minimum age requirements (often 12-18+)
• May recommend in-person evaluation for young children (especially under age 12)

Pediatric ADHD diagnosis often benefits from multiple informants (teachers, parents) and sometimes testing that’s easier to conduct in person.

Finding Quality Telehealth ADHD Care

Not all telehealth platforms are created equal. Here’s how to identify high-quality services.

What to Look for in a Telehealth ADHD Provider

✅ Licensed, credentialed clinicians: Verify that providers are MDs, DOs, NPs, or PAs licensed in your state

✅ Comprehensive evaluation process: Should include detailed questionnaires, video assessment, and symptom verification

✅ Evidence-based treatment: Providers should discuss both medication and therapy options, not just prescriptions

✅ Transparent pricing: Clear information about visit costs, medication costs, and insurance coverage

✅ Follow-up care: Ongoing monitoring and medication management, not one-time prescription services

✅ Coordination of care: Willingness to communicate with your other healthcare providers

✅ Patient education: Providers should explain medication options, side effects, and treatment expectations

Why Klarity Health Stands Out

Klarity Health offers a comprehensive approach to telehealth ADHD treatment that checks all these boxes:

• Provider availability: Get matched with licensed psychiatrists and psychiatric nurse practitioners in your state, often with same-week appointments
• Transparent pricing: Know exactly what you’ll pay—we accept both insurance and self-pay options
• Thorough evaluations: Our providers use evidence-based diagnostic tools and take time to understand your unique situation
• Ongoing support: Regular follow-ups to monitor your progress and adjust treatment as needed
• Medication flexibility: Our providers can prescribe both stimulant and non-stimulant ADHD medications (where legally permitted) based on what’s clinically appropriate for you

Whether you’re exploring ADHD treatment for the first time or looking for a more convenient way to manage existing medication, Klarity’s platform makes quality mental healthcare accessible.

Strattera vs. Stimulants: Understanding Your Options

If you’re considering telehealth ADHD treatment, it helps to understand how different medications compare.

Non-Stimulant Medications (Strattera/Atomoxetine)

How it works: Increases norepinephrine in the brain by blocking its reuptake

Benefits:

• No abuse potential or risk of dependency
• Can be prescribed with refills (no monthly visits required)
• Not a controlled substance—simpler regulatory process
• 24-hour symptom coverage
• May help with anxiety symptoms
• Doesn’t typically cause insomnia or appetite suppression

Considerations:

• Takes 4-6 weeks for full effectiveness
• May not be as immediately noticeable as stimulants
• Can cause nausea, decreased appetite, or mood changes initially
• FDA warning for potential suicidal thinking in children/adolescents (rare but monitored)
• May affect blood pressure and heart rate

Best for: Patients who:

• Have contraindications to stimulants
• Prefer non-controlled medication
• Have comorbid anxiety
• Want all-day coverage without evening doses
• Have personal or family history of substance use concerns

Stimulant Medications (Adderall, Ritalin, Vyvanse, etc.)

How they work: Increase dopamine and norepinephrine in the brain

Benefits:

• Rapid onset (work within 30-60 minutes)
• Often considered ‘first-line’ treatment for ADHD
• Many formulation options (short-acting, long-acting)
• Strong evidence base for effectiveness

Considerations:

• Controlled substances (Schedule II)—stricter prescribing rules
• Potential for misuse/diversion
• Can cause insomnia, appetite loss, anxiety
• May increase heart rate and blood pressure
• Require monthly prescriptions (no refills)
• Subject to DEA telehealth regulations

Comparison Table

Your telehealth provider will help determine which option is right for you based on your symptoms, medical history, lifestyle, and preferences.

Practical Tips for Telehealth ADHD Success

Getting the most out of telehealth ADHD treatment requires some preparation and engagement.

Before Your First Appointment

1. Gather relevant information:

• List of current medications and supplements
• Previous ADHD testing or evaluation results
• Report cards or performance reviews that document attention difficulties
• Family psychiatric history

1. Document your symptoms:

• Keep a brief journal of how ADHD affects your daily life (work, relationships, home management)
• Note when symptoms started and whether they’ve changed over time
• Consider asking a family member or close friend for their observations

1. Prepare your space:

• Find a quiet, private location for your video visit
• Test your internet connection and camera beforehand
• Have a notepad ready for questions or instructions

During Treatment

4. Track your response:

• Note any side effects, even minor ones
• Monitor symptom improvements (or lack thereof)
• Keep a medication diary for the first few weeks

4. Communicate openly:

• Be honest about whether medication is helping
• Report side effects promptly—many can be managed with dose adjustments or timing changes
• Ask questions if anything is unclear

4. Maintain regular follow-ups:

• Don’t skip appointments, even if you feel stable
• Schedule your next visit before ending the current one
• Request refills with adequate lead time (don’t wait until you’re out)

Long-Term Success

7. Combine medication with other strategies:

• Consider ADHD coaching or cognitive-behavioral therapy
• Develop organizational systems and routines
• Use apps or tools for reminders and time management

7. Build a support system:

• Educate family members about ADHD
• Connect with ADHD support communities (online or in-person)
• Work with your employer or school for appropriate accommodations

7. Stay informed about regulatory changes:

• Pay attention to communications from your telehealth provider
• Understand that rules may evolve (especially for controlled substances)
• Have a backup plan if regulations change (e.g., identify local in-person providers if needed)

What to Do If You Suspect You Have ADHD

If you’re reading this because you think you might have ADHD but haven’t been formally diagnosed, here’s what to know.

Common Adult ADHD Symptoms

Many adults with ADHD weren’t diagnosed in childhood. Watch for:

Inattention symptoms:

• Difficulty sustaining focus on tasks or conversations
• Frequent careless mistakes at work or in daily tasks
• Trouble organizing tasks and managing time
• Easily distracted by unrelated thoughts or stimuli
• Frequently losing important items
• Forgetfulness in daily activities

Hyperactivity/Impulsivity symptoms:

• Restlessness or feeling ‘driven by a motor’
• Difficulty sitting still or staying seated
• Excessive talking
• Interrupting others or difficulty waiting your turn
• Making important decisions impulsively
• Difficulty relaxing or engaging in quiet activities

When to Seek Help

Consider professional evaluation if:

• Symptoms have been present since childhood (even if undiagnosed)
• They occur in multiple settings (work, home, social situations)
• They significantly interfere with your functioning or quality of life
• You’ve tried other solutions (organization apps, time management techniques) without success

The Evaluation Process

Whether you choose telehealth or in-person care, proper ADHD evaluation includes:

• Clinical interview covering developmental history and current symptoms
• Standardized rating scales
• Review of academic/work performance history
• Assessment for other conditions (depression, anxiety, learning disabilities)
• Sometimes cognitive testing or feedback from family members

Important: ADHD often co-occurs with other conditions like anxiety or depression. A comprehensive evaluation helps identify all relevant issues so treatment can address your whole picture, not just one piece.

Getting Started with Telehealth

Platforms like Klarity Health make it easy to begin your ADHD journey:

1. Create an account and complete the intake questionnaire
2. Get matched with a licensed provider in your state
3. Schedule your video appointment—often available within days
4. Attend your evaluation from the comfort of home
5. Receive a personalized treatment plan, which may include medication, therapy referrals, or both
6. Start treatment with ongoing support and follow-up care

The entire process is designed for convenience without compromising on quality or thoroughness.

Looking Ahead: The Future of Telehealth ADHD Treatment

As we approach 2026, the telehealth landscape continues to evolve. Here’s what may change—and what will likely stay the same.

Potential Regulatory Shifts

For stimulant medications: The DEA’s temporary telehealth flexibilities expire December 31, 2025. Possible outcomes include:

• Another extension (most likely scenario based on political and healthcare industry pressure)
• New permanent rules requiring special provider registration
• Hybrid models (e.g., one in-person visit within the first 30-90 days, then telehealth continuation)
• Return to pre-pandemic rules (least likely, but possible)

For non-stimulant medications: Expect minimal changes. Since Strattera and similar medications were never subject to federal telehealth restrictions, they should remain fully accessible via telehealth regardless of what happens with controlled substance rules.

State-Level Trends

Expanding access: More states are permanently adopting pandemic-era telehealth expansions. Recent examples include New Hampshire removing in-person requirements in 2025.

Tightening safeguards: Simultaneously, states are strengthening oversight through:

• Mandatory PDMP checks
• E-prescribing requirements
• Practice standard guidelines for telehealth
• Enforcement against illegitimate online prescribers

This balanced approach aims to preserve access while preventing misuse—good news for patients seeking legitimate care.

Technology Improvements

Expect to see:

• Better integration between telehealth platforms and pharmacies
• Enhanced video consultation tools
• AI-assisted symptom tracking and medication adherence support
• Improved coordination between telehealth providers and in-person specialists

Patient Empowerment

The telehealth ADHD movement has fundamentally changed patient expectations. People now know that quality mental healthcare can be:

• Convenient and accessible
• Affordable and transparent
• Comprehensive and personalized

This shift is permanent, even if specific regulations evolve.

Your Next Steps

If you’re considering telehealth treatment for ADHD with non-stimulant medication, here’s how to move forward.

For Newly Diagnosed or Undiagnosed Individuals:

1. Research reputable telehealth platforms—look for providers with licensed clinicians, comprehensive evaluations, and transparent pricing
2. Check your insurance coverage for telehealth mental health visits
3. Gather relevant information about your symptoms and history
4. Schedule a consultation with a platform like Klarity Health that makes the process straightforward

For Currently Treated Patients Considering Telehealth:

1. Discuss with your current provider—they may offer telehealth options or can transfer your care
2. Request medical records to share with your new telehealth provider
3. Understand timing—plan for a smooth transition without gaps in medication
4. Verify state requirements if you’ve recently moved or plan to move

For Those Specifically Interested in Strattera:

1. Educate yourself about how non-stimulants work and what to expect
2. Discuss with your provider whether Strattera is appropriate for your situation
3. Set realistic expectations—remember it takes 4-6 weeks for full benefits
4. Commit to the process—regular follow-ups and open communication are key

Why Choose Klarity Health

As you explore your options, consider what makes Klarity Health different:

Accessibility: We believe everyone deserves access to quality mental healthcare. Our platform connects you with licensed providers quickly, often with same-week appointments.

Transparency: No surprise bills or hidden fees. We’re upfront about costs whether you’re using insurance or paying out-of-pocket.

Comprehensive care: Our providers don’t just write prescriptions—they take time to understand your whole story and create personalized treatment plans.

Flexibility: We accept both insurance and self-pay, making care accessible regardless of your coverage situation.

Expertise: Our network includes experienced psychiatrists and psychiatric nurse practitioners who specialize in ADHD and understand both medication and non-medication approaches.

Ongoing support: ADHD management is a journey, not a one-time event. We’re with you for regular follow-ups, medication adjustments, and any challenges that arise.

Conclusion

Getting ADHD non-stimulant medication via telehealth is not only possible—it’s often the most convenient and accessible option for many patients. Medications like Strattera are not subject to the complex controlled substance regulations that govern stimulants, making them fully available through telehealth nationwide with minimal regulatory barriers.

While state laws vary in their specific requirements, the overall trend is toward expanding telehealth access while maintaining appropriate safeguards. Whether you’re in California, Texas, Florida, New York, or anywhere else, quality telehealth ADHD care is within reach.

The key to success is choosing a reputable provider, participating actively in your evaluation and treatment, and maintaining open communication with your healthcare team. With platforms like Klarity Health offering transparent pricing, experienced providers, and comprehensive support, you can get the ADHD treatment you need without the hassle of traditional in-person appointments.

If you’ve been struggling with ADHD symptoms and wondering whether telehealth could help, there’s never been a better time to explore your options. The combination of expanded access, proven medications, and convenient care delivery means effective ADHD treatment is more accessible than ever before.

Ready to take the next step? Visit Klarity Health to learn more about our telehealth ADHD services, transparent pricing, and how we can help you get the care you deserve—from the comfort of home.

References

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescribing Controlled Substances’ – FierceHealthcare, November 2024. Available at: https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026’ – McDermott Will & Emery, 2025. Available at: https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ – Sheppard Mullin Healthcare Law Blog, National Law Review, August 15, 2025. Available at: https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. ‘The Telehealth Compliance Trap: How Alabama and New York’s Rules Could End Your Medical Practice’ – RxAgent.co, October 2025. Available at: https://www.rxagent.co/blog/telehealth-compliance-trap

5. ‘Is Strattera a Controlled Substance?’ – Medical News Today, January 14, 2025. Available at: https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. ADHD treatment should be individualized based on your specific needs and circumstances. Telehealth regulations continue to evolve—always verify current rules with your provider. If you’re experiencing a mental health emergency, call 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment